Skip to main content
. 2020 Jun 1;19:196. doi: 10.1186/s12936-020-03267-9

Table 3.

Median costs and benefits of the baseline response against malaria compared to counterfactuals, 2020–2030

Scenario comparisons (Baseline—Intervention) Clinical cases averted Reported cases averted Deaths averted Economic benefits (NPV USD) Cost (USD) (discounted)
Fully funded NSP scenario vs baseline 37,434,462 21,221,433 2683 14.1 billion 1.31 billion
Elimination scenario (HSA) vs baseline 85,571,086 51,251,099 4468 31.7 billion 961.3 million
Additional clinical cases Additional reported cases Additional deaths Additional economic losses (NPV USD)
Baseline vs reverse I 38,220,597 24,411,310 2497 14.1 billion
Baseline vs reverse II 12,974,304 8,914,008 1350 4.4 billion